{"id":917190,"date":"2025-12-08T08:59:44","date_gmt":"2025-12-08T13:59:44","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lawsuit-deadline-investors-who-purchased-over-100000-worth-of-shares-of-skye-bioscience-inc-nasdaq-skye-between-nov-2024-and-oct-2025-should-contact-the-shareholders-foundation\/"},"modified":"2025-12-08T08:59:44","modified_gmt":"2025-12-08T13:59:44","slug":"lawsuit-deadline-investors-who-purchased-over-100000-worth-of-shares-of-skye-bioscience-inc-nasdaq-skye-between-nov-2024-and-oct-2025-should-contact-the-shareholders-foundation","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lawsuit-deadline-investors-who-purchased-over-100000-worth-of-shares-of-skye-bioscience-inc-nasdaq-skye-between-nov-2024-and-oct-2025-should-contact-the-shareholders-foundation\/","title":{"rendered":"Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Skye Bioscience, Inc. (NASDAQ: SKYE) between Nov. 2024 and Oct. 2025 should contact the Shareholders Foundation"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">SAN DIEGO<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Dec. 8, 2025<\/span><\/span> \/PRNewswire\/ &#8212; The Shareholders Foundation, Inc. announces that a deadline is coming up in the lawsuit for certain investors in shares of Skye Bioscience, Inc. (NASDAQ: SKYE).<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1733185\/Shareholders_Foundation_Logo_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1733185\/Shareholders_Foundation_Logo_Logo.jpg\" title=\"Shareholders Foundation&#xD;&#xA;mail@shareholdersfoundation.com&#xD;&#xA;(8585)779-1554 (PRNewsfoto\/Shareholders Foundation, Inc.)\" alt=\"Shareholders Foundation&#xD;&#xA;mail@shareholdersfoundation.com&#xD;&#xA;(8585)779-1554 (PRNewsfoto\/Shareholders Foundation, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>Investors, who purchased between <span class=\"xn-chron\">November 4, 2024<\/span> and <span class=\"xn-chron\">October 3, 2025<\/span> in excess of <span class=\"xn-money\">$100,000<\/span> in shares of Skye Bioscience, Inc. (NASDAQ: SKYE), have certain options and there are short and strict deadlines running. Deadline: <span class=\"xn-chron\">January 16, 2026<\/span>. NASDAQ: SKYE investors should contact the Shareholders Foundation at <a href=\"mailto:mail@shareholdersfoundation.com\" rel=\"nofollow\">mail@shareholdersfoundation.com<\/a> or call +1(858) 779 &#8211; 1554.<\/p>\n<p>In <span class=\"xn-chron\">August 2024<\/span>, Skye Bioscience, Inc initiated its &#8220;CBeyond&#8221; clinical trial, a twenty-six-week, randomized, double-blind, placebo-controlled Phase 2a proof-of-concept study designed to assess nimacimab as a treatment for obesity and overweight. The CBeyond trial&#8217;s primary endpoint was to demonstrate an 8% difference in mean weight loss using nimacimab versus placebo at twenty-six weeks, with a thirteen-week follow-up.<\/p>\n<p>Then on <span class=\"xn-chron\">October 6, 2025<\/span>, Skye Bioscience, Inc issued a press release &#8220;announcing the topline data from its 26-week Phase 2a CBeyond\u2122 proof-of-concept study of nimacimab, its peripherally-restricted CB1 inhibitor antibody.&#8221; The press release disclosed that the &#8220;the nimacimab monotherapy arm did not achieve the primary endpoint of weight loss compared to placebo&#8221; and that &#8220;preliminary pharmacokinetic analysis showed lower than expected drug exposure, potentially indicating the need for higher dosing as a monotherapy.&#8221;<\/p>\n<p>On <span class=\"xn-chron\">November 17, 2025<\/span>, an investor in NASDAQ: SKYE shares filed a lawsuit over <span>alleged<\/span> securities laws violations by Skye Bioscience, Inc. The plaintiff <span>alleges<\/span> that the defendants made false and\/or misleading statements and\/or failed to disclose that nimacimab was less effective than Defendants had led investors to believe, that accordingly, nimacimab&#8217;s clinical, regulatory, and commercial prospects were overstated, and that as a result, Defendants&#8217; public statements were materially false and misleading at all relevant times.<\/p>\n<p>Those who purchased Skye Bioscience, Inc. (NASDAQ: SKYE) shares should contact the Shareholders Foundation, Inc.<\/p>\n<p>CONTACT:<\/p>\n<p>Shareholders Foundation, Inc.\u00a0<br \/>Michael Daniels\u00a0<br \/>+1 (858) 779-1554\u00a0<br \/><a href=\"mailto:mail@shareholdersfoundation.com\" target=\"_blank\" rel=\"nofollow\">mail@shareholdersfoundation.com<\/a>\u00a0<br \/>3111 Camino Del Rio North\u00a0<br \/>Suite 423\u00a0<br \/><span class=\"xn-location\">San Diego, CA<\/span> 92108<\/p>\n<p>The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock\/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and\/or settlements are not filed\/initiated\/reached and\/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=DC41021&amp;sd=2025-12-08\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/lawsuit-deadline-investors-who-purchased-over-100-000-worth-of-shares-of-skye-bioscience-inc-nasdaq-skye-between-nov-2024-and-oct-2025-should-contact-the-shareholders-foundation-302635006.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/lawsuit-deadline-investors-who-purchased-over-100-000-worth-of-shares-of-skye-bioscience-inc-nasdaq-skye-between-nov-2024-and-oct-2025-should-contact-the-shareholders-foundation-302635006.html<\/a><\/p>\n<p>SOURCE  Shareholders Foundation, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=DC41021&amp;Transmission_Id=202512080711PR_NEWS_USPR_____DC41021&amp;DateId=20251208\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire SAN DIEGO , Dec. 8, 2025 \/PRNewswire\/ &#8212; The Shareholders Foundation, Inc. announces that a deadline is coming up in the lawsuit for certain investors in shares of Skye Bioscience, Inc. (NASDAQ: SKYE). Investors, who purchased between November 4, 2024 and October 3, 2025 in excess of $100,000 in shares of Skye Bioscience, Inc. (NASDAQ: SKYE), have certain options and there are short and strict deadlines running. Deadline: January 16, 2026. NASDAQ: SKYE investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 &#8211; 1554. In August 2024, Skye Bioscience, Inc initiated its &#8220;CBeyond&#8221; clinical trial, a twenty-six-week, randomized, double-blind, placebo-controlled Phase 2a proof-of-concept study designed to assess nimacimab as a treatment for obesity and overweight. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lawsuit-deadline-investors-who-purchased-over-100000-worth-of-shares-of-skye-bioscience-inc-nasdaq-skye-between-nov-2024-and-oct-2025-should-contact-the-shareholders-foundation\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Skye Bioscience, Inc. (NASDAQ: SKYE) between Nov. 2024 and Oct. 2025 should contact the Shareholders Foundation&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-917190","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Skye Bioscience, Inc. (NASDAQ: SKYE) between Nov. 2024 and Oct. 2025 should contact the Shareholders Foundation - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lawsuit-deadline-investors-who-purchased-over-100000-worth-of-shares-of-skye-bioscience-inc-nasdaq-skye-between-nov-2024-and-oct-2025-should-contact-the-shareholders-foundation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Skye Bioscience, Inc. (NASDAQ: SKYE) between Nov. 2024 and Oct. 2025 should contact the Shareholders Foundation - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN DIEGO , Dec. 8, 2025 \/PRNewswire\/ &#8212; The Shareholders Foundation, Inc. announces that a deadline is coming up in the lawsuit for certain investors in shares of Skye Bioscience, Inc. (NASDAQ: SKYE). Investors, who purchased between November 4, 2024 and October 3, 2025 in excess of $100,000 in shares of Skye Bioscience, Inc. (NASDAQ: SKYE), have certain options and there are short and strict deadlines running. Deadline: January 16, 2026. NASDAQ: SKYE investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 &#8211; 1554. In August 2024, Skye Bioscience, Inc initiated its &#8220;CBeyond&#8221; clinical trial, a twenty-six-week, randomized, double-blind, placebo-controlled Phase 2a proof-of-concept study designed to assess nimacimab as a treatment for obesity and overweight. &hellip; Continue reading &quot;Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Skye Bioscience, Inc. (NASDAQ: SKYE) between Nov. 2024 and Oct. 2025 should contact the Shareholders Foundation&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lawsuit-deadline-investors-who-purchased-over-100000-worth-of-shares-of-skye-bioscience-inc-nasdaq-skye-between-nov-2024-and-oct-2025-should-contact-the-shareholders-foundation\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-08T13:59:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1733185\/Shareholders_Foundation_Logo_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lawsuit-deadline-investors-who-purchased-over-100000-worth-of-shares-of-skye-bioscience-inc-nasdaq-skye-between-nov-2024-and-oct-2025-should-contact-the-shareholders-foundation\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lawsuit-deadline-investors-who-purchased-over-100000-worth-of-shares-of-skye-bioscience-inc-nasdaq-skye-between-nov-2024-and-oct-2025-should-contact-the-shareholders-foundation\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Skye Bioscience, Inc. (NASDAQ: SKYE) between Nov. 2024 and Oct. 2025 should contact the Shareholders Foundation\",\"datePublished\":\"2025-12-08T13:59:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lawsuit-deadline-investors-who-purchased-over-100000-worth-of-shares-of-skye-bioscience-inc-nasdaq-skye-between-nov-2024-and-oct-2025-should-contact-the-shareholders-foundation\\\/\"},\"wordCount\":452,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lawsuit-deadline-investors-who-purchased-over-100000-worth-of-shares-of-skye-bioscience-inc-nasdaq-skye-between-nov-2024-and-oct-2025-should-contact-the-shareholders-foundation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1733185\\\/Shareholders_Foundation_Logo_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lawsuit-deadline-investors-who-purchased-over-100000-worth-of-shares-of-skye-bioscience-inc-nasdaq-skye-between-nov-2024-and-oct-2025-should-contact-the-shareholders-foundation\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lawsuit-deadline-investors-who-purchased-over-100000-worth-of-shares-of-skye-bioscience-inc-nasdaq-skye-between-nov-2024-and-oct-2025-should-contact-the-shareholders-foundation\\\/\",\"name\":\"Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Skye Bioscience, Inc. (NASDAQ: SKYE) between Nov. 2024 and Oct. 2025 should contact the Shareholders Foundation - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lawsuit-deadline-investors-who-purchased-over-100000-worth-of-shares-of-skye-bioscience-inc-nasdaq-skye-between-nov-2024-and-oct-2025-should-contact-the-shareholders-foundation\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lawsuit-deadline-investors-who-purchased-over-100000-worth-of-shares-of-skye-bioscience-inc-nasdaq-skye-between-nov-2024-and-oct-2025-should-contact-the-shareholders-foundation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1733185\\\/Shareholders_Foundation_Logo_Logo.jpg\",\"datePublished\":\"2025-12-08T13:59:44+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lawsuit-deadline-investors-who-purchased-over-100000-worth-of-shares-of-skye-bioscience-inc-nasdaq-skye-between-nov-2024-and-oct-2025-should-contact-the-shareholders-foundation\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lawsuit-deadline-investors-who-purchased-over-100000-worth-of-shares-of-skye-bioscience-inc-nasdaq-skye-between-nov-2024-and-oct-2025-should-contact-the-shareholders-foundation\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lawsuit-deadline-investors-who-purchased-over-100000-worth-of-shares-of-skye-bioscience-inc-nasdaq-skye-between-nov-2024-and-oct-2025-should-contact-the-shareholders-foundation\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1733185\\\/Shareholders_Foundation_Logo_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1733185\\\/Shareholders_Foundation_Logo_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lawsuit-deadline-investors-who-purchased-over-100000-worth-of-shares-of-skye-bioscience-inc-nasdaq-skye-between-nov-2024-and-oct-2025-should-contact-the-shareholders-foundation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Skye Bioscience, Inc. (NASDAQ: SKYE) between Nov. 2024 and Oct. 2025 should contact the Shareholders Foundation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Skye Bioscience, Inc. (NASDAQ: SKYE) between Nov. 2024 and Oct. 2025 should contact the Shareholders Foundation - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lawsuit-deadline-investors-who-purchased-over-100000-worth-of-shares-of-skye-bioscience-inc-nasdaq-skye-between-nov-2024-and-oct-2025-should-contact-the-shareholders-foundation\/","og_locale":"en_US","og_type":"article","og_title":"Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Skye Bioscience, Inc. (NASDAQ: SKYE) between Nov. 2024 and Oct. 2025 should contact the Shareholders Foundation - Market Newsdesk","og_description":"PR Newswire SAN DIEGO , Dec. 8, 2025 \/PRNewswire\/ &#8212; The Shareholders Foundation, Inc. announces that a deadline is coming up in the lawsuit for certain investors in shares of Skye Bioscience, Inc. (NASDAQ: SKYE). Investors, who purchased between November 4, 2024 and October 3, 2025 in excess of $100,000 in shares of Skye Bioscience, Inc. (NASDAQ: SKYE), have certain options and there are short and strict deadlines running. Deadline: January 16, 2026. NASDAQ: SKYE investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 &#8211; 1554. In August 2024, Skye Bioscience, Inc initiated its &#8220;CBeyond&#8221; clinical trial, a twenty-six-week, randomized, double-blind, placebo-controlled Phase 2a proof-of-concept study designed to assess nimacimab as a treatment for obesity and overweight. &hellip; Continue reading \"Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Skye Bioscience, Inc. (NASDAQ: SKYE) between Nov. 2024 and Oct. 2025 should contact the Shareholders Foundation\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lawsuit-deadline-investors-who-purchased-over-100000-worth-of-shares-of-skye-bioscience-inc-nasdaq-skye-between-nov-2024-and-oct-2025-should-contact-the-shareholders-foundation\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-08T13:59:44+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1733185\/Shareholders_Foundation_Logo_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lawsuit-deadline-investors-who-purchased-over-100000-worth-of-shares-of-skye-bioscience-inc-nasdaq-skye-between-nov-2024-and-oct-2025-should-contact-the-shareholders-foundation\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lawsuit-deadline-investors-who-purchased-over-100000-worth-of-shares-of-skye-bioscience-inc-nasdaq-skye-between-nov-2024-and-oct-2025-should-contact-the-shareholders-foundation\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Skye Bioscience, Inc. (NASDAQ: SKYE) between Nov. 2024 and Oct. 2025 should contact the Shareholders Foundation","datePublished":"2025-12-08T13:59:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lawsuit-deadline-investors-who-purchased-over-100000-worth-of-shares-of-skye-bioscience-inc-nasdaq-skye-between-nov-2024-and-oct-2025-should-contact-the-shareholders-foundation\/"},"wordCount":452,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lawsuit-deadline-investors-who-purchased-over-100000-worth-of-shares-of-skye-bioscience-inc-nasdaq-skye-between-nov-2024-and-oct-2025-should-contact-the-shareholders-foundation\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1733185\/Shareholders_Foundation_Logo_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lawsuit-deadline-investors-who-purchased-over-100000-worth-of-shares-of-skye-bioscience-inc-nasdaq-skye-between-nov-2024-and-oct-2025-should-contact-the-shareholders-foundation\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lawsuit-deadline-investors-who-purchased-over-100000-worth-of-shares-of-skye-bioscience-inc-nasdaq-skye-between-nov-2024-and-oct-2025-should-contact-the-shareholders-foundation\/","name":"Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Skye Bioscience, Inc. (NASDAQ: SKYE) between Nov. 2024 and Oct. 2025 should contact the Shareholders Foundation - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lawsuit-deadline-investors-who-purchased-over-100000-worth-of-shares-of-skye-bioscience-inc-nasdaq-skye-between-nov-2024-and-oct-2025-should-contact-the-shareholders-foundation\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lawsuit-deadline-investors-who-purchased-over-100000-worth-of-shares-of-skye-bioscience-inc-nasdaq-skye-between-nov-2024-and-oct-2025-should-contact-the-shareholders-foundation\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1733185\/Shareholders_Foundation_Logo_Logo.jpg","datePublished":"2025-12-08T13:59:44+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lawsuit-deadline-investors-who-purchased-over-100000-worth-of-shares-of-skye-bioscience-inc-nasdaq-skye-between-nov-2024-and-oct-2025-should-contact-the-shareholders-foundation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lawsuit-deadline-investors-who-purchased-over-100000-worth-of-shares-of-skye-bioscience-inc-nasdaq-skye-between-nov-2024-and-oct-2025-should-contact-the-shareholders-foundation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lawsuit-deadline-investors-who-purchased-over-100000-worth-of-shares-of-skye-bioscience-inc-nasdaq-skye-between-nov-2024-and-oct-2025-should-contact-the-shareholders-foundation\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1733185\/Shareholders_Foundation_Logo_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1733185\/Shareholders_Foundation_Logo_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lawsuit-deadline-investors-who-purchased-over-100000-worth-of-shares-of-skye-bioscience-inc-nasdaq-skye-between-nov-2024-and-oct-2025-should-contact-the-shareholders-foundation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Skye Bioscience, Inc. (NASDAQ: SKYE) between Nov. 2024 and Oct. 2025 should contact the Shareholders Foundation"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/917190","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=917190"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/917190\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=917190"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=917190"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=917190"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}